By contrast, in breast cancer [48] and glioblastoma [49] mouse models, PLX3397, another C-FMS/CSF-1R kinase inhibitor, did not affect primary tumor phenotype, but did improve the efficacy of cytotoxic chemotherapies and decreased tumor invasion, respectively. Here, CSF1R is linked to breast carcinoma.